<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02701244</url>
  </required_header>
  <id_info>
    <org_study_id>BMS-001</org_study_id>
    <nct_id>NCT02701244</nct_id>
  </id_info>
  <brief_title>A Registry Study of Breast Microseed Treatment</brief_title>
  <official_title>A Multicenter Registry Study of Breast Microseed Treatment for Early Stage Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Concure Oncology-Breast Microseed Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Concure Oncology-Breast Microseed Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      For women diagnosed with early stage breast cancer, lumpectomy followed by radiation is a
      common treatment option. Radiation treatment is typically delivered to the whole breast, five
      times per week, for anywhere from 3 to 8 weeks. The radiation helps kill any cancer cells
      that may have been left over following the surgery but causes skin burns. Many studies have
      demonstrated that radiation to the whole breast is not necessary, that it can be delivered to
      a portion of the breast where the cancer is more likely to recur.

      A technique called a Permanent Breast Seed Implant (PBSI) involving the implantation of
      radioactive seeds has been developed to deliver the radiation to a portion of the breast. The
      procedure is performed on an out-patient basis under local anesthesia and light sedation.
      Because the radioactive seeds are permanently implanted in the breast, the patient is able to
      live a normal life while the seeds deliver the prescribed radiation to the breast.

      Previous studies on PBSI demonstrate that it is a safe and effective alternative form of
      radiation for appropriately selected patients after lumpectomy. However, those results have
      been obtained mainly from a single institution, with only 4 patients treated in another
      center. Further research is still needed to evaluate its safety in a multi-center setting.
      The purpose of this study is to ensure the appropriate training of clinicians who will be
      performing this procedure and to capture long term outcomes and rare complications if any.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      For women diagnosed with early stage breast cancer, lumpectomy followed by radiation is a
      common treatment option. Radiation treatment is typically delivered to the whole breast, five
      times per week, for anywhere from 3 to 8 weeks. The radiation helps kill any cancer cells
      that may have been left over following the surgery but causes skin burns. Many studies have
      demonstrated that radiation to the whole breast is not necessary, that it can be delivered to
      a portion of the breast where the cancer is more likely to recur.

      A technique called a Permanent Breast Seed Implant (PBSI) involving the implantation of
      radioactive seeds has been developed to deliver the radiation to a portion of the breast. The
      procedure is performed on an out-patient basis under local anesthesia and light sedation.
      Because the radioactive seeds are permanently implanted in the breast, the patient is able to
      live a normal life while the seeds deliver the prescribed radiation to the breast.

      Previous studies on Permanent Breast Seed Implant (PBSI) demonstrate that it is a safe and
      effective alternative form of radiation for appropriately selected patients after lumpectomy.
      However, those results have been obtained mainly from a single institution, with only 4
      patients treated in another center. Further research is still needed to evaluate its safety
      in a multi-center setting. The purpose of this study is to ensure the appropriate training of
      clinicians who will be performing this procedure and to capture long term outcomes and rare
      complications if any.

      Due to the wide-spread use of mammography, breast cancer is commonly diagnosed at an early
      stage. The standard treatment for early-stage disease is breast conserving surgery followed
      by adjuvant radiation therapy to the whole breast. This approach leads to low recurrence
      rates with a good cosmesis and provides an effective alternative to mastectomy. However, half
      of these women will develop significant acute skin toxicity following whole breast
      irradiation. These reactions occur more frequently in the infra-mammary fold, are associated
      with pain, and are associated with a reduction in health-related quality of life. Whole
      breast radiotherapy involves several daily treatments delivered over a period of 3 to 7 weeks
      which can be disruptive for the patient's life.

      To address these drawbacks, the concept of accelerated partial breast irradiation was
      proposed. It arose out of the realization that the majority of tumor recurrences occur at or
      near the region of the prior lumpectomy site, suggesting that for well selected patients only
      the breast tissue surrounding the tumor bed might need radiation treatment. Accelerated
      partial breast irradiation limits the radiation to a smaller portion of the breast
      (surrounding the tumor cavity) and has the advantages of reducing radiation-induced toxicity
      at increased convenience because it is delivered within a much shorter period of time. In
      reducing the volume of breast treated, a higher dose of radiation can be delivered in each
      treatment session. Accelerated partial breast irradiation advantages include a reduction of
      the amount of irradiated skin and therefore the possibility to reduce radiation-induced skin
      toxicity, and an increased convenience because it can be accelerated.

      Several accelerated partial breast irradiation techniques have been reported including
      external beam conformal irradiation, intra-operative radiotherapy and brachytherapy
      techniques. Brachytherapy has been the most widely evaluated accelerated partial breast
      irradiation technique. It involves the insertion of radioactive material directly into the
      surgical cavity using tubes or catheters. Treatments are generally delivered as an outpatient
      procedure using high dose rate (HDR) brachytherapy, delivering multiple treatments (8 to 10)
      over a period of 5 to 8 days. Intra-operative radiotherapy is delivered in a single session
      at the time of initial surgery.

      A permanent breast seed implant (PBSI) technique of partial breast irradiation using
      palladium (103Pd) seeds has been proposed. Similar to a permanent seed implant used to treat
      prostate cancer, permanent breast seed implant (PBSI) involves the insertion of stranded
      radioactive seeds under ultra-sound guidance. The advantages of the permanent breast seed
      implant (PBSI) technique over other brachytherapy techniques include: i/- it is an
      out-patient procedure performed in a single one-hour session under local anesthesia and light
      sedation; ii/- it is performed after the surgery when the final pathology report is available
      and the scar is completely healed; and iii/- the use of a low dose rate technique presents
      the possible advantage to be more efficient and better tolerated compared to high dose rate
      techniques.

      The local recurrence rate, immediate and delayed toxicity, the radiation safety and quality
      assurance data suggest that permanent breast seed implant (PBSI) is a safe and acceptable
      option of accelerated partial breast irradiation, capable of delivering the right amount of
      dose in the right location for selected early stage breast cancer. However, those results
      have been obtained mainly from a single institution, with 4 patients treated in another
      center. Further research is still needed to evaluate its safety in a multi-center setting and
      also to detect serious adverse events when a larger number of patients are treated by a
      larger group of practitioners. Since brachytherapy is operator dependent, a registry
      represents a unique opportunity to ensure the appropriate training of radiation oncologist
      and to capture capturing long terms outcomes.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2016</start_date>
  <completion_date type="Anticipated">July 2026</completion_date>
  <primary_completion_date type="Anticipated">July 2021</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>10 Years</target_duration>
  <primary_outcome>
    <measure>Serious Adverse Events (SAE)</measure>
    <time_frame>Up to 10 years from procedure date</time_frame>
    <description>Serious Adverse Events (SAE) is an unintended sign, symptom, or syndrome illness that occurs during the period of observation in the clinical study and that is life threatening or result in death. Serious Adverse Events (SAE) corresponds to grade 4 or 5 signs or symptoms from the National Cancer Institute Common Toxicity Criteria for Adverse Events (NCI CTCAE) version 4.03 scale.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Breast Cancer Recurrence</measure>
    <time_frame>Up to 10 years from procedure date</time_frame>
    <description>Ipsilateral in-breast or chest wall recurrence is defined as evidence of invasive or in situ breast cancer (except lobular carcinoma in-situ (LCIS)) in the ipsilateral breast. It is important to get a pathology confirmation of the recurrence.
In case of ipsilateral recurrence or second primary breast cancer, a copy of the clinic note summarizing the localization (same quadrant, other quadrant, not specified), the pathology, the work-up and treatment plan will be submitted to the Registry. Patients will be followed beyond the diagnosis for survival assessment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Permanent Breast Seed Implant (PBSI) Side Effects</measure>
    <time_frame>At 2 months from procedure date</time_frame>
    <description>Any toxicity related to the radiation treatment, including skin and subcutaneous, or any other organ in case of seed migration will be coded using the National Cancer Institute Common Toxicity Criteria for Adverse Events (NCI CTCAE) version 4.03 scale.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Permanent Breast Seed Implant (PBSI) Side Effects</measure>
    <time_frame>Yearly up to 10 years from procedure date</time_frame>
    <description>Any toxicity related to the radiation treatment, including skin and subcutaneous, or any other organ in case of seed migration will be coded using the National Cancer Institute Common Toxicity Criteria for Adverse Events (NCI CTCAE) version 4.03 scale.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cosmetic Outcome</measure>
    <time_frame>Yearly up to 10 years from procedure date</time_frame>
    <description>Cosmetic results will be self-evaluated at each follow-up visit by the patients using the Breast Cancer Treatment Outcome Scale (BCTOS) questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival (either free of cancer or with disease present)</measure>
    <time_frame>Up to 10 years from procedure date</time_frame>
    <description>Patient survival, either free of cancer or with disease present will be recorded at follow-up appointments</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">420</enrollment>
  <condition>Breast Neoplasms</condition>
  <arm_group>
    <arm_group_label>Permanent Breast Seed Implant (PBSI)</arm_group_label>
    <description>Women with eligible early stage breast cancer who received a permanent breast seed implant status post lumpectomy</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Permanent Breast Seed Implant (PBSI)</intervention_name>
    <description>Patients are pre-planned using Computerized Tomography (CT) simulation. Implant is performed after surgery under light sedation and local freezing (alternatively general anesthesia). Stranded seeds are inserted using a brachytherapy template that is immobilized to the planned target volume using a 'localization' needle. Patients are released the same day and Quality Assurance involves post-implant Computerized Tomography (CT).</description>
    <arm_group_label>Permanent Breast Seed Implant (PBSI)</arm_group_label>
    <other_name>Breast Microseed Treatment</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients are identified during a new patient consult in each participating center.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histological diagnosis of invasive or in-situ ductal carcinoma (DCIS)

          -  Treated by breast conserving surgery with axillary node dissection (with a minimum of
             6 nodes sampled) or sentinel lymph node biopsy

          -  Surgical margins clear for invasive carcinoma (no tumor at ink margin) or superior or
             equal to 2 mm for in-situ ductal carcinoma (DCIS)

          -  A maximum tumor size of 3 cm

          -  Age â‰¥50 years old

          -  Informed consent signed if participating in the Registry

        Exclusion Criteria:

          -  No previous cancer unless in remission for more than 2 years.

          -  Active auto immune disorder with severe vasculitis component

          -  Uncontrolled and complicated insulin-dependent diabetes

          -  Pregnancy

          -  Cosmetic breast implants

          -  Psychiatric or addictive disorder that would preclude attending follow-up

          -  Post-operative breast infection requiring prolonged antibiotic therapy

          -  Lobular features on histology (pure or mixed) or sarcoma histology

          -  Node macroscopically positive on axillary dissection or in the sentinel lymph node
             biopsy

          -  Extensive in- situ carcinoma

          -  Multicentric disease (in more than one quadrant or separated by 2 cm or more)

          -  Paget's disease of the nipple

          -  Metastases

          -  Patients presenting with a large post-surgical fluid cavity as determined on the
             planning Ultrasound (US), resistant to the application of hot compresses for 4 weeks

          -  Clear delineation of the target volume on Computerized Tomography (CT) is not possible

          -  Volume to be implanted over 150cc

          -  Target volume too close to skin such that the 90% isodose overlaps the skin surface
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Juanita Crook, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>British Columbia Cancer Agency</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jean-Philippe Pignol, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Erasmus Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Juanita Crook, MD</last_name>
    <phone>+1 250 712 3958</phone>
    <email>jcrook@bccancer.bc.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jean-Philippe Pignol, MD, PhD</last_name>
    <phone>+31 10 704 13 66</phone>
    <email>j.p.pignol@erasmusmc.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Allegheny General Hospital</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15212</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Division of Radiation Oncology</last_name>
      <phone>412-359-3400</phone>
    </contact>
    <investigator>
      <last_name>Mark Trombetta, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mary Washington Hospital</name>
      <address>
        <city>Fredericksburg</city>
        <state>Virginia</state>
        <zip>22401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>John Chinault, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Swedish Cancer Institute</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Loomis</last_name>
      <phone>866-922-6237</phone>
      <email>Robert.Loomis@swedish.org</email>
    </contact>
    <investigator>
      <last_name>Stephen Eulau, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Astrid D Morris, MD, MS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Pignol JP, Rakovitch E, Keller BM, Sankreacha R, Chartier C. Tolerance and acceptance results of a palladium-103 permanent breast seed implant Phase I/II study. Int J Radiat Oncol Biol Phys. 2009 Apr 1;73(5):1482-8. doi: 10.1016/j.ijrobp.2008.06.1945. Epub 2008 Oct 18.</citation>
    <PMID>18930602</PMID>
  </reference>
  <reference>
    <citation>Pignol JP, Caudrelier JM, Crook J, McCann C, Truong P, Verkooijen HA. Report on the Clinical Outcomes of Permanent Breast Seed Implant for Early-Stage Breast Cancers. Int J Radiat Oncol Biol Phys. 2015 Nov 1;93(3):614-21. doi: 10.1016/j.ijrobp.2015.07.2266. Epub 2015 Jul 21.</citation>
    <PMID>26461003</PMID>
  </reference>
  <reference>
    <citation>Pignol JP, Keller B, Rakovitch E, Sankreacha R, Easton H, Que W. First report of a permanent breast 103Pd seed implant as adjuvant radiation treatment for early-stage breast cancer. Int J Radiat Oncol Biol Phys. 2006 Jan 1;64(1):176-81. Epub 2005 Sep 22.</citation>
    <PMID>16182464</PMID>
  </reference>
  <reference>
    <citation>Keller BM, Pignol JP, Rakovitch E, Sankreacha R, O'Brien P. A radiation badge survey for family members living with patients treated with a (103)Pd permanent breast seed implant. Int J Radiat Oncol Biol Phys. 2008 Jan 1;70(1):267-71. Epub 2007 Oct 29.</citation>
    <PMID>17967512</PMID>
  </reference>
  <reference>
    <citation>Keller B, Sankreacha R, Rakovitch E, O'brien P, Pignol JP. A permanent breast seed implant as partial breast radiation therapy for early-stage patients: a comparison of palladium-103 and iodine-125 isotopes based on radiation safety considerations. Int J Radiat Oncol Biol Phys. 2005 Jun 1;62(2):358-65.</citation>
    <PMID>15890575</PMID>
  </reference>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 25, 2016</study_first_submitted>
  <study_first_submitted_qc>March 2, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 8, 2016</study_first_posted>
  <last_update_submitted>March 16, 2018</last_update_submitted>
  <last_update_submitted_qc>March 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 19, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Infiltrating Ductal Carcinoma</keyword>
  <keyword>Ductal Carcinoma In Situ</keyword>
  <keyword>Brachytherapy</keyword>
  <keyword>Breast Neoplasms</keyword>
  <keyword>Breast Diseases</keyword>
  <keyword>Neoplasms</keyword>
  <keyword>Neoplasms by Site</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

